Condition: Multiple Myeloma, Refractory to Standard Treatment · Multiple Myeloma, Relapsed · Light Chain Amyloidosis · Sponsor: Polina Stepensky
A Phase II study of HBI0101 (NXC-201) BCMA-CART in Multiple Myeloma and Light-chain Amyloidosis Patients. The goal of the study is to evaluate the efficacy and safety of HBI0101 CART.
This description comes directly from the study's public registry record.
Polina Stepensky, MD · 972-2-6778353 · Fainak@hadassah.org.il
Always discuss trial participation with your own doctor first.
| Hadassah MO | Jerusalem, Israel | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06971380